Pfizer has reported that torcetrapib combined with all doses of atorvastatin
(Lipitor) resulted in significant increases in patients' "good" cholesterol
(HDL) levels while also significantly decreasing their "bad" cholesterol
Two Phase II studies involving the new experimental medicine were presented at the annual meeting of the American Heart Association in Dallas. The trials were designed to determine whether torcetrapib/atorvastatin therapy can effectively raise HDL cholesterol while lowering LDL cholesterol, a leading risk factor for heart disease.
In a study of nearly 500 patients, those who received torcetrapib and atorvastatin had increases in HDL cholesterol of 44 percent to 66 percent. At the same time, their LDL cholesterol dropped between 41 percent and 60 percent. Side-effects of torcetrapib/atorvastatin were similar to those most commonly associated with statin therapy.